Web Results

en.wikipedia.org/wiki/Bruesewitz_v._Wyeth

Bruesewitz v. Wyeth, 562 U.S. 223 (2011), is a United States Supreme Court case that decided whether a section of the National Childhood Vaccine Injury Act of 1986 preempts all vaccine design defect claims against vaccine manufacturers . Contents. [hide]. 1 Background; 2 Decision; 3 See also; 4 References; 5 External ...

www.oyez.org/cases/2010/09-152

Oct 12, 2010 ... Bruesewitz v. Wyeth Inc. ... Respondent. Wyeth, Inc., fka Wyeth Laboratories, et al . ... defective design. A federal judge dismissed the lawsuit, ruling that the National Childhood Vaccine Injury Act protected Wyeth from lawsuits over vaccine injury claims. The U.S. Court of Appeals for the 3rd Circuit affirmed.

caselaw.findlaw.com/us-supreme-court/09-152.html

United States Supreme Court. BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC., ET AL., (2011). No. 09-152. Argued: October 12, 2010 Decided: February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine market adversely ...

www.bprcem.com/article/S0300-595X(85)80070-0/fulltext

Phaeochromocytomas are uncommon among patients with hypertension, and sometimes occur in persons without known hypertension, but are important to detect because they are often lethal but commonly curable, and because they are a clue to the presence of associated conditions. Paroxysmal symptoms ( especially ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2674550

Aug 12, 2008 ... Objective: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial.

www.ncbi.nlm.nih.gov/pmc/articles/PMC2654064

Mar 18, 2009 ... Temsirolimus (ToriselĀ®, Wyeth pharmaceuticals), an analog of rapamycin targeting mTOR [5], represents the most successful developed compounds targeting this pathway, which has been approved for the treatment of advanced kidney ...... Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, et al.

www.ncbi.nlm.nih.gov/books/NBK109483

Husted J, Gladman D, Farewell V, Cook R. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. .... Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment .... Kavanaugh A, Krueger GG, Birbara C, Halter D, Geusens P, de Vlam K, et al.

www.nejm.org/doi/full/10.1056/NEJM200011233432103

Nov 23, 2000 ... The incidence of myocardial infarction was lower among patients in the naproxen group than among those in the rofecoxib group (0.1 percent vs. 0.4 percent; relative risk, 0.2; 95 percent confidence interval, 0.1 to 0.7); the overall mortality rate and the rate of death from cardiovascular causes were similar in ...

onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2010.03310.x/pdf

Jul 21, 2010 ... ference among the groups. Patients with definitive Py-. VAN had higher peak plasma BKV-loads and required longer time for clearance (8.8 vs. 4.6 vs. ... Schaub et al. Material and Methods. Patient population. We prospectively collected data from 206 patients transplanted between. January 2005 and June ...